Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell vaccine in newly diagnosed or recurrent glioblastoma
NCT02010606Phase 1Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jan 2014
- Primary completion
- Jan 2019
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous dendritic cell vaccine in glioblastoma (GBM), sponsored by Cedars-Sinai Medical Center. Started Jan 2014; status: completed.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02010606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010606.